Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer

Annals of Oncology

Volumn 19, Issue 8, 2008, Pages 1393-1401

  Gruber, Guenther ^a   Cole, B F ^b,p   Castiglione Gertsch, M ^c   Holmberg, S B ^d   Lindtner, J ^e   Golouh, R ^e   Collins, J ^f   Crivellari, D ^g   Thurlimann B ^a   Simoncini, E ^h   Fey, M F ⁱ   Gelber, R D ^j   Coates, A S ^k,q   Price, K N ^l   Goldhirsch, A ^m,r   Viale, G ⁿ   Gusterson, B A ^o  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b International Breast Cancer Study Group Statistical Center   (United States)

^c International Breast Cancer Study Group (IBCSG)   (Switzerland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e INSTITUTE OF ONCOLOGY   (Slovenia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h SPEDALI CIVILI   (Italy)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k International Breast Cancer Study Group   (Switzerland)

^l FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^m ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o UNIVERSITY OF GLASGOW   (United Kingdom)

^p University of Vermont ^*  (United States)

^q UNIVERSITY OF SYDNEY   (Australia)

^r EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

Axillary recurrence; Breast cancer; Extracapsular spread; Extranodal invasion; Loco regional relapse

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

EID: 48749104253     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn123     Document Type: Article

References (30)

1. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in highrisk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955.
2. Overgaard M, Jensen MB, Overgaard J et al. Posloperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-1648.
3. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-962.
4. Ceilley E, Jagsi R, Goldberg S et al. Radiotherapy for invasive breast cancer in North America and Europe: Results of a survey. Int J Radial Oncol Biol Phys 2005; 61: 365-373.
5. Katz A, Strom EA, Buchholz TA et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation, J Clin Oncol 2000; 18: 2817-2827.
6. Gruber G, Bonetti M, Nasi ML et al. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: Long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005; 23: 7089-7097.
7. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-1894.
8. Cox DR. Regression models and lifetables. J R Stat Soc B 1972; 34: 187-220.
9. Gray RJ. A class of K-sample tests for compairing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
11. Fisher BJ, Perera FE, Cooke AL et al. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: An indication for radiotherapy? Int J Radial Oncol Biol Phys 1997; 38: 551-559.
12. Kahlert S, Boettcher B, Lebeau A et al. Prognostic impact of extended extracapsular component in involved lymph nodes in pirimary breast cancer. Eur J Cancer 1999; 35: S89 Abstr 292.
13. Leonard C, Corkill M, Tomkin J et al. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer.? Implications for radiation therapy. J Clin Oncol 1995; 13: 47-53.
14. Ragaz J, Jackson S, Le N et al. Postmastectomy radiation outcome in node positive breast cancer patients among N1-3 versus N4+ subset: Impact of extracapsular spread - update of the British Columbia Randomized Trial. Proc Am Soc Clin Oncol 1999; 18: 73a Abstr 274.
15. Hetelekidis S, Schnitt SJ, Silver B et al. The significance of extracapsular extension of axillary lymph node metastases in eady-stage breast cancer. Int J Radial Oncol Biol Phys 2000; 46: 31-34.
16. Veronesi U, Rilke F, Luini A et al. Distribution of axillary node metastases by level of invasion: An analysis of 539 cases. Cancer 1987; 59: 682-687.
17. Pierce LJ, Oberman HA, Strawderman MH et al. Microscopic extracapsular extension in the axilla: Is this an indication for axillary radiotherapy? Int J Radial Oncol Biol Phys 1995; 33: 253-259.
18. Vicini FA, Horwitz EM, Lacerna MD et al. The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radial Oncol Biol Phys 199739: 1069-1076.
19. Fodor J, Toth J, Major T et al. Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: Value of adjuvant irradiation, Int J Radial Oncol Biol Phys 1999; 44: 281-287.
20. Jager JJ, Volovics L, Schouten LJ et al. Loco-regional recurrences after mastectomy in breast cancer: Prognostic factors and implications for postoperative irradiation. Radiother Oncoll 1999; 50: 267-275.
21. Gruber G, Menzi S, Forster A et al. Sites of failure in breast cancer patents with extracapsular invasion of axillary lymph node metastases no need for axillary irradiation?!. Strahenther Onkol 2005; 181: 574-579.
22. Stitzenberg KB, Meyer AA, Stem SL et al. Extracapsular extension of the sentinel lymph node metastasis: A predictor of nonsentinel node tumor burden. Ann Surg 2003; 237: 607-612.
23. Kapur U, Rubinas T, Ghai R et al. Prediction of nonsentinel lymph node metastasis in sentinel node-positive breast carcinoma. Ann Diagn Pathol 2007; 11: 10-12.
24. Fisher ER, Palekar AS, Gregorio RM et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No. 4), III: The significance of extranodal extension of axillary metastases. Am J Clin Pathol 1976; 65: 439-444.
25. Mambo NC, Gallager S. Carcinoma of the breast the prognostic significance of extranodal extension of axillary disease. Cancer 1977; 39: 2280-2285.
26. Bucci JA, Kennedy CW, Burn J et al. Implications of extranodal spread in node positive breast cancer: A review of survival and local recurrence. Breast 2001; 10: 213-219.
27. Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993; 72: 778-782.
28. Mignano JE, Zahurak ML, Chakravarthy A et al. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer 1999; 86: 1258-1262.
29. Wallgren A, Bonetti M, Gelber RD et al. Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group trials I through VII. J Clin Oncol 2003; 21: 1205-1213.
30. Strom EA, Woodward WA, Katz A et al. Clinical Investigation: Regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radial Oncol Biol Phys 2005; 63: 1508-1513.